New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2010 AND VI 28 AND IP 6
Results: 26
1
2
DH9, a novel PPAR[gamma] agonist suppresses the proliferation of ADPKD epithelial cells: an association with an inhibition of [beta]-catenin signaling.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
3
Synthesis, characterization and in vitro anti-tumor activities of novel 9-ethyl-9H-purine derivatives.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/[beta]-catenin antagonists against human osteosarcoma cells.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
5
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 834, doi. 10.1007/s10637-009-9288-7
- By:
- Publication type:
- Article
6
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34 cells.
- Published in:
- 2010
- By:
- Publication type:
- Report
7
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus.
- Published in:
- 2010
- By:
- Publication type:
- Report
8
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 854, doi. 10.1007/s10637-009-9297-6
- By:
- Publication type:
- Article
9
MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 715, doi. 10.1007/s10637-009-9303-z
- By:
- Publication type:
- Article
10
NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 729, doi. 10.1007/s10637-009-9304-y
- By:
- Publication type:
- Article
11
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 859, doi. 10.1007/s10637-009-9305-x
- By:
- Publication type:
- Article
12
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 866, doi. 10.1007/s10637-009-9306-9
- By:
- Publication type:
- Article
13
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 744, doi. 10.1007/s10637-009-9308-7
- By:
- Publication type:
- Article
14
Synthesis, characterization and in vitro anti-tumor activities of novel 9-ethyl-9 H-purine derivatives.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 754, doi. 10.1007/s10637-009-9309-6
- By:
- Publication type:
- Article
15
Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 766, doi. 10.1007/s10637-009-9311-z
- By:
- Publication type:
- Article
16
Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab.
- Published in:
- 2010
- By:
- Publication type:
- Report
17
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 783, doi. 10.1007/s10637-009-9313-x
- By:
- Publication type:
- Article
18
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.
- Published in:
- 2010
- By:
- Publication type:
- Report
19
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 839, doi. 10.1007/s10637-009-9317-6
- By:
- Publication type:
- Article
20
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 791, doi. 10.1007/s10637-009-9319-4
- By:
- Publication type:
- Article
21
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 844, doi. 10.1007/s10637-009-9321-x
- By:
- Publication type:
- Article
22
Antimetastatic activity of MONCPT in preclinical melanoma mice model.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 800, doi. 10.1007/s10637-009-9323-8
- By:
- Publication type:
- Article
23
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 812, doi. 10.1007/s10637-009-9324-7
- By:
- Publication type:
- Article
24
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 825, doi. 10.1007/s10637-009-9326-5
- By:
- Publication type:
- Article
25
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.
- Published in:
- 2010
- By:
- Publication type:
- Report
26
Erratum to: Antimetastatic activity of MONCPT in preclinical melanoma mice model.
- Published in:
- 2010
- By:
- Publication type:
- Correction Notice